The systemic availability of oral glutathione
- PMID: 1362956
- DOI: 10.1007/BF02284971
The systemic availability of oral glutathione
Abstract
When the plasma glutathione concentration is low, such as in patients with HIV infection, alcoholics, and patients with cirrhosis, increasing the availability of circulating glutathione by oral administration might be of therapeutic benefit. To assess the feasibility of supplementing oral glutathione we have determined the systemic availability of glutathione in 7 healthy volunteers. The basal concentrations of glutathione, cysteine, and glutamate in plasma were 6.2, 8.3, and 54 mumol.l-1 respectively. During the 270 min after the administration of glutathione in a dose of 0.15 mmol.kg-1 the concentrations of glutathione, cysteine, and glutamate in plasma did not increase significantly, suggesting that the systemic availability of glutathione is negligible in man. Because of hydrolysis of glutathione by intestinal and hepatic gamma-glutamyltransferase, dietary glutathione is not a major determinant of circulating glutathione, and it is not possible to increase circulating glutathione to a clinically beneficial extent by the oral administration of a single dose of 3 g of glutathione.
Similar articles
-
Effect of oral glutathione monoethyl ester and glutathione on circulating and hepatic sulfhydrils in the rat.Pharmacol Toxicol. 1994 Dec;75(6):343-7. doi: 10.1111/j.1600-0773.1994.tb00372.x. Pharmacol Toxicol. 1994. PMID: 7899255
-
Bioavailability Study of an Innovative Orobuccal Formulation of Glutathione.Oxid Med Cell Longev. 2016;2016:3286365. doi: 10.1155/2016/3286365. Epub 2015 Nov 16. Oxid Med Cell Longev. 2016. PMID: 26649136 Free PMC article.
-
High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine.Eur J Clin Invest. 1991 Feb;21(1):103-10. doi: 10.1111/j.1365-2362.1991.tb01366.x. Eur J Clin Invest. 1991. PMID: 1907548
-
L-2-oxothiazolidine-4-carboxylic acid, a cysteine prodrug: pharmacokinetics and effects on thiols in plasma and lymphocytes in human.J Pharmacol Exp Ther. 1991 Apr;257(1):331-4. J Pharmacol Exp Ther. 1991. PMID: 2019996
-
HIV-induced cysteine deficiency and T-cell dysfunction--a rationale for treatment with N-acetylcysteine.Immunol Today. 1992 Jun;13(6):211-4. doi: 10.1016/0167-5699(92)90156-2. Immunol Today. 1992. PMID: 1378279 Review.
Cited by
-
A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.Mov Disord. 2015 Oct;30(12):1696-701. doi: 10.1002/mds.26351. Epub 2015 Jul 31. Mov Disord. 2015. PMID: 26230671 Free PMC article. Clinical Trial.
-
OTC Antioxidant Products for the Treatment of Cardiovascular and other Disorders: Popular Myth or Fact?J Pharmacovigil. 2015 Apr;3(2):e136. doi: 10.4172/2329-6887.1000e136. J Pharmacovigil. 2015. PMID: 26052537 Free PMC article. No abstract available.
-
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.J Psychiatry Neurosci. 2011 Mar;36(2):78-86. doi: 10.1503/jpn.100057. J Psychiatry Neurosci. 2011. PMID: 21118657 Free PMC article. Review.
-
Possible involvement of the JAK/STAT signaling pathway in N-acetylcysteine-mediated antidepressant-like effects.Exp Biol Med (Maywood). 2016 Mar;241(5):509-18. doi: 10.1177/1535370215619707. Epub 2015 Dec 6. Exp Biol Med (Maywood). 2016. PMID: 26643864 Free PMC article.
-
Deletion of the lactoperoxidase gene causes multisystem inflammation and tumors in mice.Sci Rep. 2021 Jun 14;11(1):12429. doi: 10.1038/s41598-021-91745-8. Sci Rep. 2021. PMID: 34127712 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical